Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-791 Receptor Occupancy in MS and IPF
NCT06683612Phase 1Completed
- Sponsor
- Contineum Therapeutics
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PIPE-791 in multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Contineum Therapeutics. Primary endpoints: LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan and LPA1 occupancy as determined by regional total volume of distribution (VT) at each lung scan. Started Dec 2024; status: completed.
02
Drugs
PIPE-791
03
Conditions
multiple sclerosis (MS)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06683612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683612.